4.7 Article

Antimicrobial activity of cefepime/zidebactam (WCK 5222), a β-lactam/β-lactam enhancer combination, against clinical isolates of Gram-negative bacteria collected worldwide (2018-19)

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Infectious Diseases

In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy

Isabel Barcelo et al.

Summary: Resistance development to cefepime/zidebactam in Pseudomonas aeruginosa required multiple simultaneous mutations that were associated with significant impairment of fitness and virulence.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)

Review Microbiology

New beta-Lactam-beta-Lactamase Inhibitor Combinations

Dafna Yahav et al.

CLINICAL MICROBIOLOGY REVIEWS (2020)

Review Pharmacology & Pharmacy

An update on beta-lactamase inhibitor discovery and development

Jean-Denis Docquier et al.

DRUG RESISTANCE UPDATES (2018)

Article Infectious Diseases

In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria

David M. Livermore et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)